The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Merck Serono
 
Craig Underhill
Consulting or Advisory Role - AstraZeneca; Bayer; Merck Serono
Speakers' Bureau - AstraZeneca; IQvia
Research Funding - Akeso Biopharma (Inst); Arcus Biosciences (Inst); AtriCure (Inst); BeyondSpring Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); novotech (Inst)
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - ANZUP; Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - ANZUP; Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Astellas Pharma; Bayer; Imagion Biosystems
Research Funding - Astellas Pharma
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen-Cilag; MSD Oncology; Pfizer
 
Mark Voskoboynik
Honoraria - MSD
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Alpine Immune Sciences (Inst); Antengene (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Atridia (Inst); BeiGene (Inst); Hengrui Pharmaceutical (Inst); Hinova Pharmaceuticals (Inst); MSD (Inst); Virocure (Inst)
 
Xinghai Li
Employment - Hinova Pharmaceuticals
Leadership - Hinova Pharmaceuticals
Stock and Other Ownership Interests - Hinova Pharmaceuticals
 
Ivan King
No Relationships to Disclose
 
Lisa Shao
Employment - Hinova Pharmaceuticals
 
Yiyun Dai
Employment - Hinova Pharmaceuticals
 
Frank Perabo
Employment - Tachyon Therapeutics
Leadership - Tachyon Therapeutics
Stock and Other Ownership Interests - Alnylam; Aurinia Pharmaceuticals; Black Diamond Therapeutics; JNJ; MAIA Biotechnology; Tachyon Therapeutics; Travere Therapeutics; Turning Point Therapeutics
Consulting or Advisory Role - Hinova Pharmaceuticals; Pattern Pharma; Purespring Therapeutics; Radius Health
Patents, Royalties, Other Intellectual Property - KDM4 patents